Mayo Clinic, Rochester

Site:	Mayo Clinic, Rochester	Go to their website
Address:
City:	Rochester
State:	MN
Zip:	55905
Country:	USA

12 trials at this site

Phase [asc]	Trial	Trial Status	Site Status	Drug	NCT#
1	A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors	Ongoing, but not recruiting	Closed	MEDI-573	NCT00816361
1	Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	Completed	Closed	Navitoclax + Sorafenib	NCT02143401
1	A Study of XmAb®18087 in Subjects With NET and GIST	Active, not recruiting	Closed	XmAb18087	NCT03411915
2	An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment	Completed	Closed	BIIB021 (CNF2024)	NCT00618319
2	CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor	Completed	Closed	CCI-779	NCT00087074
3	Masitinib 2nd Line versus Sunitinib in Advanced GIST	Unknown	Active	Masitinib or Sunitinib	NCT01694277
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Active, not recruiting	Active, not recruiting	Bezuclastinib plus Sunitinib	NCT05208047
3	A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)	Recruiting	Active	Ripretinib	NCT05734105
1/2	Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion	Recruiting	Active	MRTX1719	NCT05245500